Patent
Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
TLDR
In this article, l'invention concerne l'utilisation, dans une composition pharmaceutique destinee a la prevention and au traitement des tumeurs induites par les papillomavirus, en particulier le virus HPV-16, d'un poxvirus recombinant comportant une sequence d'ADN heterologue codant au moins.Abstract:
L'invention concerne l'utilisation, dans une composition pharmaceutique destinee a la prevention et au traitement des tumeurs induites par les papillomavirus, en particulier le virus HPV-16, d'un poxvirus recombinant comportant une sequence d'ADN heterologue codant au moins pour la region essentielle d'une proteine non structurale d'un papillomavirus ainsi que les elements de regulation assurant son expression dans les cellules superieures. Plus particulierement, il s'agit des proteines E5, E6, E7 du virus HPV-16.read more
Citations
More filters
Patent
Papillomavirus polyprotein constructs
Elizabeth Ann Webb,Mary Brigid Margetts,John Cooper Cox,Ian H. Frazer,Nigel Alan John Mcmillan,Mark Philip Williams,Margaret Bridget Holland Moloney,Stirling John Edwards +7 more
TL;DR: A Papillomarivus polyprotein construct comprises at least two amino acid sequences fused directly or indirectly together, each of the sequences being the sequence of an early ORF protein of papillomavirus or an immunogenic variant or fragment thereof as discussed by the authors.
Patent
Human papilloma virus immunoreactive peptides
Samir N. Khleif,Jay A. Berzofsky +1 more
TL;DR: In this article, the authors provide immunogenic peptides from the HPV-18E6 protein that comprise class I restricted T cell epitopes and discloses methods of administering these peptides to individuals.
References
More filters
Journal ArticleDOI
Comparison of the in vitro transforming activities of human papillomavirus types.
TL;DR: It is demonstrated that the E7 gene of HPV16 by itself is sufficient to co‐operate with activated ras to produce transformed cells which are tumorigenic in immunocompetent animals.
Journal ArticleDOI
Tumour prevention and rejection with recombinant vaccinia.
Richard Lathe,Marie-Paule Kieny,Pierre Gerlinger,Philippe Clertant,Ikram Guizani,François Cuzin,Pierre Chambon +6 more
TL;DR: Examining whether live vaccinia virus recombinants expressing TSA in cells of the vaccinated host might better elicit tumour immunity concluded that tumour-bearing animals could be induced to reject their tumours by inoculation of recombinant.
Journal ArticleDOI
Analysis of the L1 Gene Product of Human Papillomavirus Type 16 by Expression in a Vaccinia Virus Recombinant
TL;DR: Antibodies to a beta-galactosidase fusion protein containing a C-terminal portion of the HPV16 L1 gene product were used to compare the levels of L1 expression in the two recombinants, and showed that greater levels of expression were obtained when the gene was placed under the control of the 4b late promoter.